Condition: Advanced Solid Tumors · Sponsor: Teva Branded Pharmaceutical Products R&D LLC
The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Determine a RP2D of TEV-56278 in combination with pembrolizumab The secondary objectives of this trial are to: * Characterize the serum pharmacokinetics of TEV-56278 * Evaluate the antitumor activity of TEV-56278 * Determine the safety and tolerability of TEV-56278 * Evaluate other measures of antitumor activity of TEV-56278 * Evaluate anti-tumor activity Participants will be treated up to 12 months with a follow-up period of up to 12 months after last infusion. The total duration of the trial will be up to 25 months for individual participants. Participants who exhibit a favorable benefit risk profile at the end of the 12 month trial treatment period may be offered an opportunity for an extended treatment period in which they can be treated for a maximum of 12 additional months (up to 26 additional cycles of TEV-56278).
This description comes directly from the study's public registry record.
Teva U.S. Medical Information · 1-888-483-8279 · USMedInfo@tevapharm.com
Always discuss trial participation with your own doctor first.
| Teva Investigational Site 12017 | Los Angeles, California, United States | Recruiting |
| Teva Investigational Site 12021 | Lake Mary, Florida, United States | Completed |
| Teva Investigational Site 12016 | Chicago, Illinois, United States | Recruiting |
| Teva Investigational Site 12015 | Detroit, Michigan, United States | Recruiting |
| Teva Investigational Site 12014 | Huntersville, North Carolina, United States | Recruiting |
| Teva Investigational Site 12023 | Cincinnati, Ohio, United States | Recruiting |
| Teva Investigational Site 12058 | Pittsburgh, Pennsylvania, United States | Recruiting |
| Teva Investigational Site 12019 | Nashville, Tennessee, United States | Recruiting |
| Teva Investigational Site 12024 | Nashville, Tennessee, United States | Recruiting |
| Teva Investigational Site 12018 | Fairfax, Virginia, United States | Recruiting |
| Teva Investigational Site 12025 | Milwaukee, Wisconsin, United States | Recruiting |
| Teva Investigational Site 11282 | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06480552